$113.87
-0.68-0.59%
At Close: -
$112.50
-1.37-1.20%
After Hours: Aug 23, 4:08 PM EDT
15 minutes delayed
Companies issue guidance, or expectations of future EPS and revenue, so investors have a sense of how much money a company will make in a future period.
The most recent guidance for Jazz Pharmaceuticals (JAZZ) was reported on July 31, 2024 for the full year 2024. The company provided earnings per share guidance in the range of $19.20 to $20.30, compared to the estimated EPS of $18.51. Additionally, Jazz Pharmaceuticals forecasted revenue between $4.00B and $4.10B for the quarter.
Browse guidance and forecast on all stocks.